About EP Vantage

EP Vantage is a new forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas.

Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers.

EP Vantage was founded by EvaluatePharma, the industry leader in consensus forecasts. Our unique access to EvaluatePharma Alpha’s Calendar of Events allows coverage of potential market catalysts weeks and even months ahead of other industry sources, while Alpha’s interactive NPV Analyzer puts events into context.

These are some of the reasons why we can count executives from 18 of the top 20 pharmaceutical companies and four out of five of the top investment banks working in the sector among our growing readership.